Clotblog with Dr Samuel GoldhaberView all posts »
FDA approval of apixaban for stroke prevention in AF: The "tipping point" for novel oral anticoagulantsJan 11, 2013 09:20 EST
With three novel drugs—dabigatran, rivaroxaban, and now apixaban—approved for stroke prevention in AF, the tide is changing on oral anticoagulation. It's time to set aside our (very human) tendency to avoid change and acknowledge the evidence for the uptake of these new agents.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992. Abstract.
Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2012; DOI:10.1056/NEJMoa1207541. Abstract.